Abstract: Compositions and methods are provided for tissue constructs that promote wound healing. The composition comprises a dimensionally stable fibrin construct for local administration to a wound site or region. In one embodiment, the fibrin construct is a wound healing composition, including components that promote wound healing, such as platelets, growth factors, white blood cells and fibrin clots. In another embodiment, the tissue treatment composition includes (i) aggregated fibrin, (ii) blood cells, and (iii) optionally, growth factors and/or other proteins.

Abstract: A method of treating a patient who has extravasation of blood from an intravascular compartment to an extravascular compartment. An agent is administered to the patient which mitigates a harmful effect of break-down products of blood at an extravascular site, resulting in the patient having reduced morbidity and mortality. The morbidity and mortality of the patient is further reduced by concomitant administration of a suspension of submicron protein spheres having a molecular weight of ranging from 780 billion Daltons to less than 0.8 billion Daltons.

Abstract: The present invention encompasses an antithrombotic nanoparticle.

Abstract: In an embodiment of the disclosure, a biomedical material is provided. The biomedical material includes a biocompatible material having a surface and a carrier distributed over the surface of the biocompatible material, wherein both of the biocompatible material and the carrier have no charges, one of them has charges or both of them have charges with different electricity. The biomedical material is utilized for dentistry, orthopedics, wound healing or medical beauty and applied in the repair and regeneration of various soft and hard tissues.

Abstract: Described herein are devices and techniques for spray drying a fluid to produce a dried powder. Assemblies include a spray drying head attachable to a gas supplier and a liquid sample, such as a standard unit of blood product. The spray drying head can be adapted to provide an aerosolized flow of liquid sample exposed to a drying gas. The assembly also includes a drying chamber adapted to separate the aerosolized flow of liquid sample into a dried powder and humid air. The assembly can be disposable, provided in a sterilized kit and having simplified attachments allowing quick connect and disconnect from the gas and liquid sample. Separation of the powder from the humid air exiting the drying chamber occurs within a filtered collection bag. In some embodiments, one or more of the drying chamber and collection bag are formed form a thin-walled, collapsible material.

Abstract: The disclosure relates to methods for detecting PNH Type II cell populations in biological samples as well as methods for determining whether a patient is at an increased risk for developing thrombocytopenia or thrombosis based on the percentage of PNH Type II cells in the patient's blood. The disclosure also features reagents and conjugates for use in the methods.

Abstract: A method of treating a natural soft skeletal tissue injury in a patient the method comprising administering to the patient a composition of mesenchymal stem cells in liquid suspension enriched compared to the natural source of said cells, or tenocytes derived therefrom. The method is particularly suited to the regeneration of tendons in competitive mammals, such as the superficial digital flexor tendon of the horse.

Abstract: Described herein are devices and techniques for spray drying a fluid to produce a dried powder. Assemblies include a spray drying head attachable to a gas supplier and a liquid sample, such as a standard unit of blood product. The spray drying head can be adapted to provide an aerosolized flow of liquid sample exposed to a drying gas. The assembly also includes a drying chamber adapted to separate the aerosolized flow of liquid sample into a dried powder and humid air. The assembly can be disposable, provided in a sterilized kit and having simplified attachments allowing quick connect and disconnect from the gas and liquid sample. Separation of the powder from the humid air exiting the drying chamber occurs within a filtered collection bag. In some embodiments, one or more of the drying chamber and collection bag are formed form a thin-walled, collapsible material.

Abstract: A mouse with a humanization of the mIL-3 gene and the mGM-CSF gene, a knockout of a mRAG gene, and a knockout of a mII2rg subunit gene; and optionally a humanization of the TPO gene is described. A RAG/II2rg KO/hTPO knock-in mouse is described. A mouse engrafted with human hematopoietic stem cells (HSCs) that maintains a human immune cell (HIC) population derived from the HSCs and that is infectable by a human pathogen, e.g., S. typhi or M. tuberculosis is described. A mouse that models a human pathogen infection that is poorly modeled in mice is described, e.g., a mouse that models a human mycobacterial infection, wherein the mouse develops one or more granulomas comprising human immune cells. A mouse that comprises a human hematopoietic malignancy that originates from an early human hematopoietic cells is described, e.g., a myeloid leukemia or a myeloproliferative neoplasia.

Abstract: A method for augmenting a tissue including introducing into the tissue a first thermoplastic material at a first condition; treating the first thermoplastic material to achieve a second condition that includes an at least partially crystalline skin; and introducing a second material into the tissue whereby the first thermoplastic material and the second material are contained by the at least partially crystalline skin. Also a method of fracture reduction in a tissue including exposing to gamma radiation a mass of polycaprolactone characterized by a first shape; heating the mass of irradiated polycaprolactone above its melting temperature; introducing the heated mass of polycaprolactone into the tissue annulus to deform it from the first shape; allowing the material to return to the first shape.

Abstract: Compositions for platelet rich plasma (PRP) and neutrophil-depleted PRP are provided. Methods for treating ischemia damaged tissues by delivering a PRP composition, in some embodiments a neutrophil-depleted PRP composition to the damaged tissue are provided. In some variations, the compositions may be useful to treat ischemic heart disease and repair damaged cardiovascular tissue following acute myocardial infarction including congestive heart failure. In some variations, the compositions may be useful to reduce cardiac apoptosis after a heart attack.

Abstract: The invention provides a single surgical procedure by using autologous platelet-rich fibrin (PRF) and cartilage fragments to solve problems of contamination during incubation of chondrocytes and transplant rejection in vivo, which has the benefit of a more efficient and shorter recovery time. The invention also provides a device for easily and rapidly cutting cartilage to cartilage fragments so as to reduce contamination of the implant and infection.

Abstract: The invention is directed toward a sterile formable implant composition for application to a bone defect site comprising bioactive glass particles in an aqueous carrier solution, the bioactive glass particles being added to a viscous carrier at a concentration ranging from about 68% to about 76% (w/w), the carrier comprising a mixture of glycerol and polyethylene glycol ranging from 24% to 32% (w/w) with the ratio of glycerol to polyethylene glycol ranging from about 45:55 to about 65:35.

Abstract: The present disclosure relates to an activated polymer composition for use in repairing tissue of a patient comprising platelet-rich plasma (PRP), a chitosan solution, a salt such as NaCl or glycerol phosphate, and an activator such as at least one of CaCI2 and a mixture of thrombin/CaCI2.

Abstract: The present invention provides methods for detecting, analyzing, and identifying biomolecules used to identifying patient with dengue-like symptom who are at risk of DHF. The inventive method comprises detecting in a sample from a subject dengue infected patient one or more biomarkers selected from the group consisting of IL-10, fibrinogen, C4A, immunoglobulin, tropomyosin, and three isoforms of albumin, and which are used in a predictive MARS model to detect patients with risk of developing DHF.

Abstract: The present invention relates to methods, compositions and kits for increasing the in vivo circulation time of isolated platelets by storing the platelets with one or more sialidase inhibitors.

Abstract: Modified Factor IX (FIX) polypeptides and uses thereof are provided. Such modified FIX polypeptides include FIXa and other forms of FIX. Among the modified FIX polypeptides provided are those that have altered activities, typically altered procoagulant activity, including increased procoagulant activities. Hence, such modified polypeptides are therapeutics.

Abstract: The present invention relates to a platelet additive solution (PAS) having an amount of one or more sialidase inhibitors and optionally one or more glycan-modifying agents; and one or more of PAS components that includes a salt, a citrate source, a carbon source, and any combination thereof.

Abstract: Embodiments of the present invention include a surgical kit for preparation of a patch for implantation into a human body, characterized in that it comprises a package containing, on one hand, a synthetic substrate (1) and, on the other hand, means for treatment of the substrate with a solution (3) including at least one biologically active component (4, 5), adapted to integrate the biologically active component with the substrate. Embodiments of the invention include a patch for implantation into the human body, comprising a synthetic substrate (1), characterized in that at least one biologically active component (4, 5) is integrated with the substrate using the surgical kit.

Abstract: The invention is directed to a method of accelerating healing in a joint comprising administering a platelet composition to the joint.

Abstract: Provided are methods of treating cardiac infarction by using an injectable material to influence cardiac structure and remodeling after infarction. Also provided are kits that comprise an injectable material to influence cardiac structure.

Abstract: The present invention relates to a material for induction of hard tissue regeneration, comprising platelet-rich plasma and gelatin ?-TCP sponge, which promotes angiogenesis, osteogenesis, chondrogenesis and the like.

Abstract: This disclosure describes systems, methods, and apparatus for forming concentrates of platelet-rich plasma or bone marrow cells having user-defined concentrations, concentration ranges, and/or volumes. Whole blood or bone marrow samples can be passed through one or two separation operations in which platelets or bone marrow cells are separated from red blood cells and concentrated in a plasma. During this separation and concentrating, a total number of platelets or bone marrow cells or a concentration of either is determined and then used to ascertain what volumes and concentrations need be mixed in order to produce a platelet-rich plasma concentrate or a bone marrow-rich plasma concentrate having a target concentration and/or volume.

Abstract: The present invention includes a method for activating platelets in a platelet solution, the method may include passing the platelet solution through an activator at least once to activate at least one of the platelets in the platelet solution to produce an activated platelet solution. The activator may further include a flow disruption element. The method may further induce administering the activated platelet solution to the repair site of a patient. The present invention may also be a system for treating a medical condition at a repair site within a patient in need thereof, which may include a platelet solution container for housing a platelet solution; an activator to activate at least one platelet; and an introducer to direct the at least one activated platelet to the repair site.

Abstract: Provided herein are compositions for treating wounds, method of making and using the system thereof. The system for treating a wound includes a first composition having cetylpyridinium chloride, Aloe vera, and ascorbic acid for sanitizing a wound. The system includes a second composition having concentrated platelet-rich plasma and a hypertonic saline solution for activating granulation of the wound. The system includes a third composition having Aloe vera, ascorbic acid, vitamin A, vitamin E and immunoglobulins for initiating re-epithelialization of the wound.

Abstract: The present invention provides modified platelets having a reduced platelet clearance and methods for reducing platelet clearance. Also provided are compositions for the preservation of platelets. The invention also provides methods for making a pharmaceutical composition containing the modified platelets and for administering the pharmaceutical composition to a mammal to mediate hemostasis.

Abstract: An apparatus for the preparation of cells for implantation into a living body is disclosed. The apparatus comprises a vessel substantially impermeable to gaseous oxygen; and fluid within said vessel, the fluid having a maximal dissolved oxygen capacity substantially equivalent to normal saline yet having a hypoxic oxygen concentration between about 0% to about 5% of said maximal dissolved oxygen capacity. The bag oxygen concentration level remains low when the apparatus is stored at 22°-25° C. in normal atmospheric conditions for a period of at least 30 days. The present invention simplifies the process of achieving donor cell hypoxic preconditioning for cell implantation, and may be used to bathe said cells to be transplanted for a sufficient time to activate the hypoxic metabolic pathway.

Abstract: A semi-synthetic platelet gel comprising a platelet-rich plasma, at least one platelet activator, and a biocompatible polymer selected from the group comprising carbomers, polyalkylene glycols, poloxamers, polyesters, polyethers, polyanhydrides, polyacrylates, polyvinyl acetates, polyvinyl pyrrolidones, polysaccharides, and derivatives thereof. A method for preparing a semi-synthetic platelet gel comprising the steps of (a) mixing a platelet-rich plasma with at least one platelet activator, and, before the start of clot formation, (b) adding the mixture thus obtained to a biocompatible polymer selected from the group comprising carbomers, polyalkylene glycols, poloxamers, polyesters, polyethers, polyanhydrides, polyacrylates, polyvinyl acetates, polyvinyl pyrrolidones, polysaccharides, and derivatives thereof.

Abstract: Methods are described for using compositions containing platelet-rich plasma for the treatment of acute or chronic dysfunction of cardiac muscle. The method may employ a kit which includes a platelet-rich plasma composition and a pH adjusting agent and a catheter or syringe for delivery of the platelet-rich plasma composition to dysfunctional cardiac muscle. The kit may also include a syringe for withdrawing blood from a patient and a centrifuge device means to obtain platelet-rich plasma.

Abstract: Methods, apparatus, and compositions related to a method of treating erectile dysfunction in a subject, the method comprising administering a composition comprising platelet-rich plasma at or proximate to ischemic tissue comprising the corpora cavernosa or corpus spongiosum.

Abstract: The present invention provides modified platelets having a reduced platelet clearance and methods for reducing platelet clearance. Also provided are compositions for the preservation of platelets. The invention also provides methods for making a pharmaceutical composition containing the modified platelets and for administering the pharmaceutical composition to a mammal to mediate hemostasis.

Abstract: Manufacturing and Purification Processes of Complex Protein found in Fraction IV to make a separated Apo, Transferrin, and Alpha 1 Antitrypsin (A1AT) or a combined Transferrin/Apo/Human Albumin/A1AT and all new found proteins. A complex of all proteins found currently in Plasma, Cryoprecipitate, Fraction III and many newly found proteins now being identified or any substances which are known proteins or unknown proteins which contain GOOD HEALTHY CELLS and the combination of any of these known or unknown proteins which contain any one of these GOOD HEALTHY cells: Neutrophil, Lymphocyte, Eosinophil, Basophil, and Marcophage, and their potential applications for treating a wide variety of diseases and other physical conditions and disorders, and for maintaining health.

Abstract: Provided herein are methods of using amnion derived adherent cells, and populations of, and compositions comprising, such cells, in the modulation of an immune response. In various embodiments, the immune response is graft-versus-host disease, an allergy, asthma, or an immune-related disease or disorder, e.g., an autoimmune disease.

Abstract: Provided herein are compositions comprising placental stem cells and platelet rich plasma. Also provided herein are methods of treating an individual suffering from a disease or condition that would benefit from reduced inflammation, promotion of angiogenesis, and enhanced healing, comprising administering a therapeutically effective amount of a composition comprising placental stem cells and platelet rich plasma, as described herein, to said individual in an amount and for a time sufficient for detectable improvement of said disease or condition.

Abstract: Methods are described for using compositions containing platelet-rich plasma for the treatment of a cancer in a variety of tissues. Particularly, treatment of brain cancer with platelet releasate is described.

Abstract: The present invention provides pharmaceutical compositions, and methods of preparation and use for the treatment, prevention or alleviation of bone and cartilage diseases or injuries and hair loss. The present invention discloses a method and a pharmaceutical composition comprising mesenchymal stem cells, platelets, activating factors and scaffolding materials for the treatment, prevention, or alleviation of bone diseases, bone injuries or hair loss, and a method and a pharmaceutical composition further comprising dexamethasone for the treatment, prevention, or alleviation of cartilage diseases or injuries.

Abstract: The present invention provides pharmaceutical compositions, and methods of preparation and use for the treatment, prevention or alleviation of bone and cartilage diseases. The present invention discloses a method and a pharmaceutical composition comprising adipose-derived stem cells, platelet rich plasma, calcium chloride, and hyaluronic acid for the treatment, prevention, or alleviation of bone diseases, and a method and a pharmaceutical composition further comprising dexamethasone for the treatment, prevention, or alleviation of cartilage diseases.

Abstract: This document provides methods and materials involved in treating burn injuries. For example, methods and materials for using skin grafts (e.g., autologous skin grafts) treated with an autologous platelet concentrate and autologous thrombin to treat burn injuries (e.g., deep skin burn injuries) are provided.

Abstract: A method of regenerating tissue in a living organism. The method includes the act of contacting an affected area of the living organism with a solid-fibrin web, the solid-fibrin web comprising platelets that release growth factors about one minute after contact to regenerate the tissue in the living organism.

Abstract: A conformable tissue implant is provided for use in repairing or augmenting a tissue defect or injury site. The tissue implant contains a tissue carrier matrix comprising a plurality of biocompatible, bioresorbable granules and at least one tissue fragment in association with the granules. The tissue fragment contains one or more viable cells that can migrate from the tissue and populate the tissue carrier matrix. Also provided is a method for injectably delivering the tissue implant.

Abstract: A lymphocytotoxic, but hematopoietic stem cell-sparing, high-dose amount of an oxazaphosphorine drug such as, for example, cyclophosphamide, administered post-transplantation can be used to reduce transplant rejection, including graft-versus-host-disease (GVHD). In some embodiments, the transplants are bone marrow transplants or hematopoietic stem cell transplants carried out for the treatment of hematologic disorders, including hematologic malignancies and non-malignant hematologic disorders. In some embodiments, the transplants are carried out for the treatment of hereditary hemoglobinopathies, such as sickle cell anemia and thalassemia.

Abstract: A bio-membrane with angiogenic activity for implant in tissue regeneration and repair, including bone reconstruction and the repair of skin and soft tissue lesions is described, essentially constituted by a gel able to provide support and growth and/or differentiation and/or angiogenic factors for the full in vivo functionality of the cell, containing also mesenchymal stem/precursor cells, an implant device for reconstructive surgery of bone tissue, of skin and soft tissue lesions which comprises the bio-membrane, and a method for its obtainment. Use of the gel alone for tissue regeneration and of adhesive plasters that comprise it is also described.

Abstract: A method for preparing a blood component composition for reducing risk of transfusion related injury includes passing a blood component composition through a tangential flow filter unit comprising one or more filter membranes. A diafiltration solution is added to the blood component composition during the filtration process. Non-cellular plasma components, including antibodies, are removed from the blood component composition by the tangential flow filtration.

Abstract: Fixed-dried blood cells carrying an active agent are described, along with methods of making the same, methods of using the same, and compositions containing the same. The blood cells are preferably blood platelets.

Abstract: The present invention regards a biological material comprising: a) a liquid carrier comprising a viscous solution containing at least one natural and/or semisynthetic polysaccharide, and having a Dynamic viscosity measured at 20° C. and at shear rate of D=350 s?1, comprised between 100 and 250 c Poise and/or a Kinematic viscosity comprised between 99 and 248cSt (measured at the same conditions); b) a culture of mesenchymal stem cells, and/or c) a platelet-rich hemo-derivative. This type of material in form of viscous liquid is particularly suitable for the therapy of osteoarthrosis, ligament damage, in particular tendon and cartilage damage) and may be administered intra-articularly, intradermally or directly applied in situ without altering the properties of the mesenchymal stem cells and/or platelets contained therein.

Abstract: A semi-synthetic platelet gel comprising a platelet-rich plasma, at least one platelet activator, and a biocompatible polymer selected from the group comprising carbomers, polyalkylene glycols, poloxamers, polyesters, polyethers, polyanhydrides, polyacrylates, polyvinyl acetates, polyvinyl pyrrolidones, polysaccharides, and derivatives thereof. A method for preparing a semi-synthetic platelet gel comprising the steps of (a) mixing a platelet-rich plasma with at least one platelet activator, and, before the start of clot formation, (b) adding the mixture thus obtained to a biocompatible polymer selected from the group comprising carbomers, polyalkylene glycols, poloxamers, polyesters, polyethers, polyanhydrides, polyacrylates, polyvinyl acetates, polyvinyl pyrrolidones, polysaccharides, and derivatives thereof.

Abstract: Kits are described for the treatment of acute or chronic dysfunction of cardiac muscle. The kit includes a platelet-rich plasma composition with a pH adjusting agent and a catheter or syringe for delivery of the platelet-rich plasma composition to dysfunctional cardiac muscle. The kit may also include a syringe for withdrawing blood from a patient and a centrifuge device to obtain platelet-rich plasma.

Abstract: Methods and compositions for the prevention or reduction of platelet transfusion associated complications are provided. Methods are provided to modify donor platelets prior to transfusion to prevent or reduce alloimmune platelet refractoriness.

Abstract: Provides are improved methods for storing platelets and compositions that contain stored platelets for use in transfusions. The method entails obtaining a platelet concentrate from blood obtained from an individual and holding the platelet concentrate in at refrigerated temperatures under an atmosphere having a pressure of from 3.5 to 5 bars comprising more than 65% xenon and for at least one week. Also provided is a refrigerated composition that contains a platelet concentrate, wherein the platelet concentrate contains xenon, and wherein the platelet concentrate has been isolated from an individual for at least seven days.

Abstract: A hair growth agent having an effective dose of a platelet dry powder and a pharmaceutically acceptable solvent and/or excipient, wherein the effective dose refers to the presence of at least 1,000 platelets in every milligram of the hair growth agent.